NCT03161418 - Study of the Safety of KSP Heptapeptide (KSP-910638G) | Biotech Hunter

Enrollment

26

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

September 20, 2017

Study Completion Date

September 20, 2017

Conditions

Healthy Adults

Interventions

DRUG

KSP-910638G, 0.4 mg

The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)

DRUG

KSP-910638G, 1.2 mg

The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)

Trial Locations (1)

48109

University of Michigan, Ann Arbor